(NASDAQ: RLAY) Relay Therapeutics's forecast annual revenue growth rate of 31.99% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Relay Therapeutics's revenue in 2025 is $10,007,000.On average, 3 Wall Street analysts forecast RLAY's revenue for 2025 to be $2,604,872,732, with the lowest RLAY revenue forecast at $1,034,083,279, and the highest RLAY revenue forecast at $5,085,655,470. On average, 4 Wall Street analysts forecast RLAY's revenue for 2026 to be $5,653,892,708, with the lowest RLAY revenue forecast at $169,521,849, and the highest RLAY revenue forecast at $13,088,781,961.
In 2027, RLAY is forecast to generate $3,000,875,771 in revenue, with the lowest revenue forecast at $305,139,328 and the highest revenue forecast at $6,390,973,707.